Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Johnson & Johnson

Pfizer

UnitedHealth Group

Health and wealth; it doesn't get much better than that.

Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever

Abbott Laboratories said on Friday it expects to begin releasing EleCare formula next week from its recently reopened Sturgis plant, which has been at the center of a baby formula shortage in the United States.

Abbott expects to start shipping EleCare infant formula next week

A rise in the number of procedures performed will likely aid the company's medical devices sales, offsetting any decline in the diagnostics business, given that the segment benefited from higher Covid-19 testing in the prior-year quarter.

Will Abbott Stock Rise After Its Q2 Results?

H.B. Fuller

Lowe's

Altria

MSA Safety

Parker-Hannifin

PPG Industries

Stanley Black & Decker

Sysco

Target

Tennant

The 44 Dividend Kings finished June in the red, collectively losing 5.39%. Last month, the 11 best dividend kings based on forecasted growth and valuation underperformed the average dividend king return by 152 bps.

My 11 Best Dividend Kings For July 2022

Intuitive Surgical

Attractive returns should be on the way for these companies' shareholders.

2 Top Healthcare Stocks to Buy and Hold for the Long Haul

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Abbott (ABT) Q2 Earnings Expected to Decline

Federal Realty Investment Trust

Kimberly-Clark

PepsiCo

Dividend Kings are usually looked at as a safer bet than other investments because it gives you stable income during market volatility. The post 5 Dividend Kings That Income Investors Can Count On appeared first on InvestorPlace.

5 Dividend Kings That Income Investors Can Count On

Abbott (NYSE: ABT) announced that the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), which is a form of major depressive disorder (MDD). These are the details.

Abbott (ABT) Receives FDA's Breakthrough Device Designation For Exploring Deep Brain Stimulation To Manage Severe Depression

Breakthrough Device Designations are given by the U.S. FDA to expedite the review of technologies that can improve the lives of people with life-threatening or debilitating conditions Each year, 2.8 million Americans will fail multiple depression therapies and be diagnosed with treatment-resistant depression (TRD) With Breakthrough Device Designation, Abbott's deep brain stimulation (DBS) System could become available as a new treatment option sooner for people affected by TRD ABBOTT PARK, Ill., July 12, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD).

Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression

DexCom

These dividend-paying superstars have been raising their payouts for generations.

2 Dividend Stocks You Can Confidently Buy in a Bear Market

Allstate

Cisco Systems

Investors looking for stocks that could potentially outperform are encouraged to consider the GF Score at the top of each summary page.

4 Undervalued Names With Very High GF Scores

Production is again underway at the Abbott Labs facility in Michigan which was shutdown twice this year amid the baby formula crisis.

Abbott's troubled baby formula factory back in business

Abbott Laboratories has reopened its Sturgis, Michigan baby formula plant, which was shut last month due to heavy rains, a company spokesperson told Reuters on Saturday.

Abbott says it has reopened Michigan baby formula plant

Costco

STERIS

These businesses operate on a large scale but with a narrower focus than Amazon.

3 Stalwart Stocks That Could Be Safer Than Amazon

This marks an outperformance compared to some of its peers, with Medtronic stock rising around 1%, Boston Scientific stock up 9%, Stryker stock seeing a 30% growth, and the S&P 500 index rising 54% over the same period.

Should You Buy Abbott Stock At $110?

Los Angeles, California--(Newsfile Corp. - July 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or "the Company") (NYSE: ABT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abbott was the subject of testimony by Dr. Robert Califf, the head...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - July 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or "the Company") (NYSE: ABT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abbott was the subject of testimony by Dr. Robert Califf, the head...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm

Abbott was caught in a middle of the infant formula crisis. 92% of the market is occupied by three companies, the closure of the plant in Michigan led to disastrous consequences.

Abbott: Successfully Handled The Infant Formula Crisis

Los Angeles, California--(Newsfile Corp. - July 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or "the Company") (NYSE: ABT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abbott was the subject of testimony by Dr. Robert Califf, the head...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm

Reliable cash flows and decades-long track records make these stocks screaming buys right now.

2 of the Safest Stocks to Buy in a Recession

Abbott has declined for roughly six consecutive months, falling about 40% from its late 2021 peak. Abbott seemed to bounce off of the $100 per share price on the last leg down, and that may end up being extreme support in the near term.

Abbott Finds Support Around $100

EssilorLuxottica SA

ESLOY vs. ABT: Which Stock Is the Better Value Option?

ESLOY or ABT: Which Is the Better Value Stock Right Now?

Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Abbott Laboratories (“Abbott”) (NYSE: ABT) breached their fiduciary duties to Abbott and its shareholders. If you are an Abbott shareholder, you are encouraged to contact attorney Joe Pettigrew with Scott+Scott for additional information at (844) 818-6982 or jpettigrew@scott-scott.c

ABBOTT LABORATORIES INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Continues to Investigate Abbott Laboratories' Directors and Officers for Breach of Fiduciary Duties – ABT

News for Abbott Labs Stock (ABT)